NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has completed the second tranche of a previously announced $5 million placement of stock and convertible debentures.

In the new tranche, the firm sold newly registered convertible debentures, which can be converted into about 2.6 million ordinary shares, for gross proceeds of $1.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.